July 6, 2020 / 12:41 PM / a month ago

BRIEF-Myovant Sciences Presents Additional Data On Relugolix Combination Therapy

July 6 (Reuters) - Myovant Sciences Ltd:

* MYOVANT SCIENCES PRESENTS ADDITIONAL DATA ON RELUGOLIX COMBINATION THERAPY FROM PHASE 3 LIBERTY STUDIES IN WOMEN WITH UTERINE FIBROIDS AND FROM OVULATION INHIBITION STUDY

* MYOVANT SCIENCES - DATA FROM PHASE 3 LIBERTY PROGRAM SHOW IMPROVEMENT IN PATIENT-REPORTED OUTCOMES IN ADDITION TO IMPROVEMENT IN HEMOGLOBIN LEVELS

* MYOVANT SCIENCES LTD - DETAILED DATA FROM OVULATION INHIBITION STUDY DEMONSTRATE 100% OVULATION INHIBITION

* MYOVANT SCIENCES - OPEN-LABEL EXTENSION STUDY MET PRIMARY ENDPOINT WITH RELUGOLIX COMBINATION THERAPY DEMONSTRATING AN 87.7% RESPONSE RATE AT ONE YEAR

* MYOVANT SCIENCES LTD - WOMEN EXPERIENCED, ON AVERAGE, AN 89.9% REDUCTION IN MENSTRUAL BLOOD LOSS FROM BASELINE AT WEEK 52 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below